Skip to main
CATX

CATX Stock Forecast & Price Target

CATX Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Perspective Therapeutics is a leading radiopharmaceutical company that has a unique technology utilizing the alpha-emitting isotope Lead-212 to target and treat cancer cells with minimal side effects, making it a promising treatment option in the evolving NET treatment paradigm. With positive updated data from its Phase 1/2a study of VMT-α-NET at AACR 2026, including an overall response rate of 60% and an excellent safety profile, the company is well-positioned for continued success in clinical trials and potential commercialization. However, there are risks to consider, such as competition and potential challenges with reimbursement and adoption.

Bears say

Perspective Therapeutics is a clinical stage biotech company with a proprietary technology for delivering radiation to cancer cells, but their current pipeline lacks solid data and precise targeting moieties. Additionally, their aggressive dosing approach may compromise efficacy and the company's high valuation can be considered overvalued considering their limited clinical progress and lack of commercial success.

CATX has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Perspective Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Perspective Therapeutics Inc (CATX) Forecast

Analysts have given CATX a Strong Buy based on their latest research and market trends.

According to 8 analysts, CATX has a Strong Buy consensus rating as of Jul 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Perspective Therapeutics Inc (CATX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.